Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 25 Squamous Cell Carcinoma of Head and Neck 10 Lung Neoplasms 10 Neoplasms 6 Neoplasm Metastasis 6 Head and Neck Neoplasms 6 Esophageal Squamous Cell Carcinoma 5 Breast Neoplasms 5 Pancreatic Neoplasms 4 Carcinoma, Squamous Cell 4 Stomach Neoplasms 3 Esophageal Neoplasms 3 Brain Neoplasms 3 Prostatic Neoplasms 2 Non-small-cell Lung Cancer With Somatic EGFR Mutations 2 NSCLC 2 Glioblastoma 2 Colorectal Neoplasms 2 Adenocarcinoma of Lung 2 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Unilateral HER2 Positive Breast Cancer 1 Triple Negative Breast Neoplasms 1 Thrombocytosis 1 Thoracic Neoplasms 1 Squamous Cell Cancers of the Head and Neck 1 Solid Tumors 1 Small Cell Lung Carcinoma 1 Skin Neoplasms 1

Interventions

Trastuzumab 1 Paclitaxel 1 Epirubicin 1 Cyclophosphamide 1 Afatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Unilateral HER2 Positive Breast Cancer × Afatinib × Clear all

NCT01594177 2014-03-13

DAFNE

GBG Forschungs GmbH

Phase 2 Completed

Unilateral HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡